Technology
Health
Biotechnology

AnaptysBio

$52.85
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$1.06 (-1.97%) Today
$0.00 (0.00%) As of 3:52 PM EDT after-hours

Why Robinhood?

You can buy or sell AnaptysBio and other stocks, options, ETFs, and crypto commission-free!

About ANAB

AnaptysBio, Inc. Common Stock, also called AnaptysBio, is a clinical stage biotechnology company, which engages in developing antibody product candidates focused on unmet medical needs in inflammation. Read More Its pipeline includes ANB020, ANB019, and checkpoint receptor agonist antibodies. The company was founded by Andrew B. Cubitt, William J. Boyle and Nicholas B. Lydon in November 2005 and is headquartered in San Diego, CA.

Employees
78
Headquarters
San Diego, California
Founded
2005
Market Cap
1.46B
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
207.98K
High Today
$53.85
Low Today
$52.30
Open Price
$53.75
Volume
285.63K
52 Week High
$110.00
52 Week Low
$51.73

Collections

Technology
Health
Biotechnology
Medical
2017 IPO
US
North America

ANAB News

Yahoo FinanceJun 21

Here's Why AnaptysBio Shares Are Sliding Today

316
Seeking AlphaJun 21

AnaptysBio -3% as bull runs to sidelines

142
Seeking AlphaJun 21

AnaptysBio -13.8% on Regeneron data, downgrades

163

ANAB Earnings

-$0.92
-$0.71
-$0.51
-$0.30
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Estimated
Actual
Expected Aug 6, After Hours

More ANAB News

All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.